Journal article

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.

  • Lyon AR Cardio-Oncology Service, Royal Brompton Hospital and Imperial College, London, UK.
  • Dent S Duke Cancer Institute, Duke University, Durham, NC, USA.
  • Stanway S Breast Unit, Royal Marsden Hospital, Surrey, UK.
  • Earl H Department of Oncology, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK.
  • Brezden-Masley C Division of Medical Oncology, Sinai Health System, Mount Sinai Hospital, Toronto, Canada.
  • Cohen-Solal A UMR-S 942, Paris University, Cardiology Department, Lariboisiere Hospital, AP-HP, Paris, France.
  • Tocchetti CG Department of Translational Medical Sciences and Interdepartmental Center for Clinical and Translational Research (CIRCET), Federico II University, Naples, Italy.
  • Moslehi JJ Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Groarke JD Cardio-Oncology Program, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Bergler-Klein J Department of Cardiology, Medical University of Vienna, Vienna, Austria.
  • Khoo V Department of Clinical Oncology, Royal Marsden Hospital and Institute of Cancer Research, London, UK.
  • Tan LL Department of Cardiology, National University Heart Centre, Singapore, National University Health System, Singapore, Singapore.
  • Anker MS Division of Cardiology and Metabolism, Department of Cardiology, Charité and Berlin Institute of Health Center for Regenerative Therapies (BCRT) and DZHK (German Centre for Cardiovascular Research), partner site Berlin and Department of Cardiology, Charité Campus Benjamin Franklin, Berlin, Germany.
  • von Haehling S Department of Cardiology and Pneumology, University of Goettingen Medical Center, Goettingen, Germany.
  • Maack C Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany.
  • Pudil R First Department of Medicine - Cardioangiology, Charles University Prague, Medical Faculty and University Hospital Hradec Kralove, Prague, Czech Republic.
  • Barac A MedStar Heart and Vascular Institute, Georgetown University, Washington, DC, USA.
  • Thavendiranathan P Ted Rogers Program in Cardiotoxicity Prevention and Joint Division of Medical Imaging, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada.
  • Ky B University of Pennsylvania, Philadelphia, PA, USA.
  • Neilan TG Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Belenkov Y Sechenov Medical University, Moscow, Russia.
  • Rosen SD Cardio-Oncology Service, Royal Brompton Hospital and Imperial College, London, UK.
  • Iakobishvili Z Department of Community Cardiology, Tel Aviv Jaffa District, Clalit Health Fund and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Sverdlov AL School of Medicine and Public Health, University of Newcastle and "Cancer and the Heart" Program, Hunter New England LHD, Newcastle, Australia.
  • Hajjar LA Cardio-Oncology, Department of Cardio-Pneumology, University of São Paulo, São Paulo, Brazil.
  • Macedo AVS Santa Cardio-Oncology, Santa Casa de São Paulo and Rede Dor São Luiz, São Paulo, Brazil.
  • Manisty C Barts Heart Centre and University College London, London, UK.
  • Ciardiello F Department of Precision Medicine, Luigi Vanvitelli University of Campania, Naples, Italy.
  • Farmakis D University of Cyprus Medical School, Nicosia, Cyprus.
  • de Boer RA Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Skouri H Cardiology Division, Internal Medicine Department, American University of Beirut Medical Center, Beirut, Lebanon.
  • Suter TM Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.
  • Cardinale D Cardioncology Unit, European Institute of Oncology, IRCCS, Milan, Italy.
  • Witteles RM Stanford University School of Medicine, Stanford, CA, USA.
  • Fradley MG University of Pennsylvania, Philadelphia, PA, USA.
  • Herrmann J Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
  • Cornell RF Vanderbilt University Medical Center, Nashville, TN, USA.
  • Wechelaker A National Amyloidosis Centre, University College London, London, UK.
  • Mauro MJ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Milojkovic D Department of Haematology, Hammersmith Hospital, Imperial College, London, UK.
  • de Lavallade H Department of Haematological Medicine, King's College Hospital, London, UK.
  • Ruschitzka F University Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.
  • Coats AJS University of Warwick, Warwick, UK.
  • Seferovic PM Faculty of Medicine and Serbian Academy of Sciences and Arts, University of Belgrade, Belgrade, Serbia.
  • Chioncel O Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', Bucharest, Romania.
  • Thum T Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany.
  • Bauersachs J Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
  • Andres MS Cardio-Oncology Service, Royal Brompton Hospital and Imperial College, London, UK.
  • Wright DJ Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, Liverpool, UK.
  • López-Fernández T Cardiology Service, Cardio-Oncology Unit, La Paz University Hospital and IdiPAz Research Institute, Ciber CV, Madrid, Spain.
  • Plummer C Department of Cardiology, The Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, UK.
  • Lenihan D Cardio-Oncology Center of Excellence, Washington University in St Louis, St Louis, MO, USA.
Show more…
  • 2020-05-29
Published in:
  • European journal of heart failure. - 2020
English This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.
Language
  • English
Open access status
hybrid
Identifiers
Persistent URL
https://sonar.ch/global/documents/33318
Statistics

Document views: 55 File downloads:
  • Full-text: 0